In a report released today, Chris Schott from J.P. Morgan upgraded Amneal Pharmaceuticals (AMRX – Research Report) to a Buy, with a price target of $12.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Chris Schott has given his Buy rating due to a combination of factors positioning Amneal Pharmaceuticals for robust growth. The company has shown strong execution with the Crexont launch, which is outperforming expectations and contributing significantly to revenue projections. The generics segment of AMRX is well-positioned due to a strategic shift towards complex products and biosimilars, which is expected to support high single-digit growth over the coming years.
Another factor contributing to Schott’s rating is the performance of AvKARE, which has demonstrated consistent growth exceeding 20% over the past two years. This segment is anticipated to maintain its momentum, bolstering the company’s overall topline growth despite lower margins. Additionally, AMRX’s strategic positioning and execution are expected to result in healthy revenue and EPS growth, with 2025 revenue forecasts reaching approximately $3 billion and EPS estimates being revised upwards. Overall, these factors suggest strong underlying business fundamentals, supporting the Buy rating.
Schott covers the Healthcare sector, focusing on stocks such as Pfizer, Gilead Sciences, and Eli Lilly & Co. According to TipRanks, Schott has an average return of 2.0% and a 52.03% success rate on recommended stocks.